Featured Research

from universities, journals, and other organizations

Spleen might be source of damaging cells at spinal cord injury site

Date:
November 16, 2010
Source:
Ohio State University
Summary:
The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests. Considering the spleen's role in the after-effects of spinal cord injury could change the way researchers pursue potential treatments for these devastating injuries.

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

Considering the spleen's role in the after-effects of spinal cord injury could change the way researchers pursue potential treatments for these devastating injuries.

In the days and weeks after the spinal cord is damaged, a variety of cells travel to the wound site. In a typical wound, such as a cut on the skin, cells like this cooperate to promote healing.

But the spinal cord environment is not typical. It is specialized tissue in a confined and delicate space. And when its own cells and other cells join to protect the wound, some cells end up promoting inflammation, which can exacerbate the effects of the injury.

Most research in this area has explored the bone marrow as a source of these pro-inflammatory cells, called macrophages, but some previous studies have suggested that the spleen is another source.

An Ohio State University study showed an overall 20 percent drop in the number of these macrophages two weeks after spinal cord injury in mice without a spleen when compared to injured mice that still had their spleens. The research suggests that the spleen might be a potential target for therapies designed to either inhibit release of these cells or alter their function.

"The spleen is releasing cells that are traveling to the injury site and it's a significant number of cells," said Alicia Hawthorne, a postdoctoral researcher in neuroscience at Ohio State who led the study. "If we could target the spleen to decrease these cells or change their properties and make them less destructive, this might help promote the repair process as opposed to letting them cause inflammation or further damage to neurons."

Hawthorne presented the research in a poster session on November 14 at the Society for Neuroscience annual meeting in San Diego.

The researchers compared the characteristics of spinal cord injury sites in two groups of mice: those whose spleens had been removed before the injury and those that still had their spleens. These injuries were in the T-9 region, roughly the middle of the back, and caused paralysis in the animals' hind limbs.

Fourteen days after the injury, the mice without spleens showed an overall 20 percent decrease in macrophage activity at the injury site compared to mice with their spleens.

To ensure the spleen was the likely source of these cells, the researchers also analyzed the characteristics of cells in the bone marrow, blood, spleen and spinal cord. They found that the spleen's cells were very similar to the cells circulating through the blood to the spinal cord site. The cells start out as monocytes, a different type of white blood cell, and then change into macrophages, which promote inflammation at the injury site.

The spinal cord itself is yet another source of macrophages at the injury site, but the researchers believe these so-called "resident" cells do more good than harm. It's the intense peripheral cell immune response in spinal cord injury, where sensitive tissue and blood vessels are essentially ripped apart and form a traumatic wound, that the scientists someday hope to control in an effort to improve function after the injury.

Knowing more about the cells coming from the spleen could have important clinical implications. The spleen is seen as an excellent drug target, the researchers say, because it filters blood, making intravenous drug delivery easy and effective.

"If we can understand how these cells function and can understand the sequence with which they're released and migrate to the spinal cord, we can manipulate them. How do we manipulate them? That's something we don't know yet," said Phillip Popovich, professor of neuroscience, director of Ohio State's Center for Brain and Spinal Cord Repair and senior co-author of the study. "Understanding the dynamics of the cell population outside the central nervous system will improve our ability to control inflammation once it's triggered by a trauma."

This work was supported by the National Institute for Neurological Disorders and Stroke and the Ray W. Poppleton Endowment.

Additional co-authors include Zhen Guan and Dustin Donnelly of the Center for Brain and Spinal Cord Repair at Ohio State.


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "Spleen might be source of damaging cells at spinal cord injury site." ScienceDaily. ScienceDaily, 16 November 2010. <www.sciencedaily.com/releases/2010/11/101115101141.htm>.
Ohio State University. (2010, November 16). Spleen might be source of damaging cells at spinal cord injury site. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/11/101115101141.htm
Ohio State University. "Spleen might be source of damaging cells at spinal cord injury site." ScienceDaily. www.sciencedaily.com/releases/2010/11/101115101141.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins